FDA Reviewer Form

Proposal Number:	Applicant's Name:
Department:	Number of Years at K-State:
Summary:	

Evaluation Criteria	Range	Score	Comments
Priority Weighting		-	
Years at K-State: 5 pts ≤ 3years, 3 pts > 3 & ≤ 5 years, 1			
pt > 5 years	1, 3, 5		
Funding Level:	2, 3, 3		
5: No startup funds or discipline where limited funding is			
availabe			
3: well-funded, but grants do not cover international			
travel; between grants and funding needed to present			
work; or using a sizable amount of startup as			
supplemental funding			
0: startup funds but not used as supplemental funding;			
well-funded and no reason given why these funds can't			
be used for travel	0,3,5		
Reason for Travel:			
3-5: Invited (needs to be documented and substantiated			
as prestigious);			
4: Award;			
3: Visit Sponsor or selected by peer review			
2: Poster session or attend workshop/colloquia			
1: International meeting in US (points can be added if			
significance of meeting is well articulated)	0 to 5		
Non-Narrative			
Is the budget well laid out, justified and complete with		1	
documentation (Orbitz/conference printouts) and			
explanation for the costs?	0 to 10		
'	0 to 5		
Is the itinerary well laid out and informative? How well does the department head's letter form	0 10 3		
support the PI's attendance at the meeting? Is the form			
complete?	0 to 5		
Abstract/Narrative			
Does the abstract summarize the proposal well? It			
should summarize the FDA narrative not the paper to be			
presented.	0 to 5		
presented		+	
Is the significance of the meeting well explained?	0 to 10		
How well does the proposal address networking and			
collaboration at the meetings? Are specific groups or			
individuals mentioned? Is a networking approach or			
strategy discussued?	0 to 10		
Hanning Hide and hannes and address have the control of			
How well does the proposal address how the meetings fit	0 to 10		
into the PIs overall career and research plans?	0 10 10	+	
Is any future outreach planned for the presentation			
beyond the meeting attended (e.g., publication in a			
journal, inclusion in meeting proceedings, exhibition catalog, press release)?	0 to 10		
	0.0010	+	
What is your rating of the potential outcomes of the PI attending the meeting?	0 to 10		
Overall			
Overall impression of this submission: take into account			
how well (e.g., outputs/outcomes) previous FDA/USRG			
funding has been utilized. Is the proposal well laid out			
and organized?	0 to 10		
Total	0 to 100	0	

Strengths:

Weaknesses/Suggestions for Improvement:

Overall Recommendation:	Fund-High Priority; Fund-Lower Priority;	Fund if Can-High; Fund if	
Can-Low; Do not Fund			